The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical trial and translational research for cancer immunology in Asian countries: Understanding the new frontier.
 
Mel Valerie Cruz Ordinario
No Relationships to Disclose
 
Yuki Kojima
No Relationships to Disclose
 
Kazuki Sudo
Honoraria - AstraZeneca; Eisai; Pfizer
Research Funding - AstraZeneca; Daiichi Sankyo; NanoCarrier; Pfizer
 
Namiko Iida
Honoraria - Abbvie (I); Janssen (I); Novartis (I)
Research Funding - Chugai Pharma (I)
Other Relationship - AIR WATER INC; Clinigen Group; JCR Pharmaceuticals
 
Shinichiro Okamoto
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - Chugai Pharma; IQvia; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Keisuke Watanabe
Honoraria - Agilent
Consulting or Advisory Role - Janssen
 
Marcelo Severino Bulauitan Imasa
Speakers' Bureau - AstraZeneca; Eisai; MSD; Pfizer; Roche
Research Funding - AstraZeneca; MSD; Pfizer; Roche